0000000000340475

AUTHOR

Magnus Nilsson

showing 9 related works from this author

Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy

2019

Objective: The aim of this study was to describe anastomotic techniques used for total minimally invasive transthoracic esophagectomy (ttMIE) and to analyze the associated morbidity. Background: ttMIE faces increasing application in surgical treatment of esophageal cancer. For esophagogastric reconstruction, different anastomotic techniques are currently used, but their effect on postoperative anastomotic leakage and morbidity has not been investigated. Patients and Methods: Patients were selected from a basic dataset, collected during a 5-year period from 13 international surgical high-volume centers. Endpoints were anastomotic leakage rate and postoperative morbidity in correlation to ana…

medicine.medical_specialtybusiness.industryRetrospective cohort studyTransthoracic esophagectomyEsophageal cancerAnastomosismedicine.disease3. Good healthSurgery03 medical and health sciences0302 clinical medicineAnastomotic leakageInterquartile range030220 oncology & carcinogenesismedicine030211 gastroenterology & hepatologySurgeryComplicationbusinessSurvival analysisAnnals of Surgery
researchProduct

Combined Innovation Policy: Linking Scientific and Practical Knowledge in Innovation Systems

2012

New research indicates that firms combining the science-based STI (Science, Technology, Innovation) and the experience-based DUI (Doing, Using, Interacting) modes of innovation are more efficient when it comes to improving innovation capacity and competitiveness. With regard to innovation policy, the STI mode calls for a supply driven policy, typically aimed to commercialise research results. The DUI mode suggests a demand driven policy approach, such as supporting the development of new products or services to specific markets. This paper analyses how the two types of innovation policy and the two innovation modes can be combined in regional innovation systems. The analysis builds on studi…

9. Industry and infrastructure05 social sciencesGeography Planning and Development0211 other engineering and technologiesInnovation management021107 urban & regional planning02 engineering and technologyPolicy initiativesInnovation policy Regional system of innovation Modes of innovation Food industry Agribusiness Farm Management Food Consumption/Nutrition/Food Safety Industrial Organization Research Methods/ Statistical Methods0502 economics and businessEconomicsMarketing050203 business & managementIndustrial organizationAgribusiness
researchProduct

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherap…

2020

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or esophageal adenocarcinoma …

0301 basic medicineCancer Researchmedicine.medical_specialtyPhases of clinical researchIpilimumabchemotherapylcsh:RC254-282gastroesophageal cancer03 medical and health sciences0302 clinical medicineadjuvantClinical endpointMedicineddc:610ipilimumabperioperativenivolumabbusiness.industrygastric cancerStandard treatmentgastric cancer gastroesophageal cancer immunotherapy chemotherapy adjuvant nivolumab ipilimumab perioperativePerioperativeEsophageal cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseClinical TrialSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapyNivolumabbusinessadjuvant; chemotherapy; gastric cancer; gastroesophageal cancer; immunotherapy; ipilimumab; nivolumab; perioperativemedicine.drug
researchProduct

FA01.02: THE EFFECT OF POSTOPERATIVE COMPLICATIONS AFTER MIE ON LONG-TERM SURVIVAL: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY.

2018

Abstract Background Esophagectomy has a high incidence of postoperative morbidity. Complications lead to a decreased short-term survival, however the influence of those complications on long-term survival is still unclear. Most of the performed studies are small, single center cohort series with inconclusive or conflicting results. Minimally invasive esophagectomy (MIE) has been shown to be associated with a reduced postoperative morbidity. In this study, the influence of complications on long-term survival for patients with esophageal cancer undergoing a MIE were investigated. Methods Data was collected from the EsoBenchmark database, a collaboration of 13 high-volume centers routinely per…

AdultMalemedicine.medical_specialtyTime FactorsDatabases FactualEsophageal Neoplasmsmedicine.medical_treatmentAnastomotic LeakKaplan-Meier EstimateSingle Center03 medical and health sciencesPostoperative Complications0302 clinical medicineSDG 3 - Good Health and Well-beingmedicineHumansMinimally Invasive Surgical ProceduresAgedRetrospective Studiesbusiness.industryIncidence (epidemiology)GastroenterologyRetrospective cohort studyGeneral MedicineMiddle AgedEsophageal cancermedicine.diseaseSurgeryEsophagectomyLog-rank testTreatment OutcomeEsophagectomy030220 oncology & carcinogenesisCohortFemale030211 gastroenterology & hepatologybusinessCohort study
researchProduct

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus

2021

Summary There are no internationally recognized criteria available to determine preparedness for hospital discharge after esophagectomy. This study aims to achieve international consensus using Delphi methodology. The expert panel consisted of 40 esophageal surgeons spanning 16 countries and 4 continents. During a 3-round, web-based Delphi process, experts voted for discharge criteria using 5-point Likert scales. Data were analyzed using descriptive statistics. Consensus was reached if agreement was ≥75% in round 3. Consensus was achieved for the following basic criteria: nutritional requirements are met by oral intake of at least liquids with optional supplementary nutrition via jejunal fe…

medicine.medical_specialtydischarge criteriaConsensusDelphi Techniquemedicine.medical_treatmentDelphi methodVital signs03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterSurveys and QuestionnairesmedicineHumansFeeding tubecomputer.programming_languageHospital stayDescriptive statisticsddc:617business.industryGastroenterologyGeneral Medicinemedicine.diseaseColorectal surgeryDischarge criteriahospital stayPatient Discharge3. Good healthEsophagectomyDelphi consensusEsophagectomy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyMedical emergencyOutcomes researchbusinesscomputerDelphi
researchProduct

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence…

2021

TPS4156 Background: Gastroesophageal adenocarcinoma (GEA) patients with metastatic lymph nodes (ypN+) or a microscopically incomplete surgical resection (R1) following neoadjuvant chemotherapy are at high risk of disease recurrence. Current practice is to continue with the same perioperative chemotherapy used prior to surgery, despite these suboptimal outcomes. Adjuvant immunotherapy with nivolumab has shown efficacy in poor risk GEA patients following chemoradiotherapy and surgery in the CheckMate 577 trial, and nivolumab and ipilimumab have demonstrated activity in advanced GEA. We hypothesise that high risk (ypN+ and/or R1) post resection GEA patients who are treated with nivolumab and …

Cancer ResearchChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchCancerImmunotherapymedicine.diseaseOncologyMedicinePreoperative chemotherapyIn patientLymphRadiologybusinessAdjuvantJournal of Clinical Oncology
researchProduct

The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north-south gradient among Europeans.

2016

Idiopathic achalasia is a severe motility disorder of the esophagus and is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus. Most recently, we identified an eight-amino-acid insertion in the cytoplasmic tail of HLA-DQβ1 as strong achalasia risk factor in a sample set from Central Europe, Italy and Spain. Here, we tested whether the HLA-DQβ1 insertion also confers achalasia risk in the Polish and Swedish population. We could replicate the initial findings and the insertion shows strong achalasia association in both samples (Poland P=1.84 × 10(-04), Sweden P=7.44 × 10(-05)). Combining all five European data sets - Central E…

0301 basic medicineMaleEuropean Continental Ancestry GroupShort ReportAchalasiaHuman leukocyte antigenWhite People03 medical and health sciences0302 clinical medicineSwedish populationGeneticGenetics esophageal achalasiaMutation RateGeneticsmedicineotorhinolaryngologic diseasesPrevalenceHLA-DQ beta-ChainsHumansIn patientEsophagusRisk factorGenetics (clinical)GeneticsHLA-DQ beta-ChainPolymorphism Geneticbusiness.industryEuropean populationmedicine.diseaseEsophageal AchalasiaEuropeMutagenesis Insertional030104 developmental biologymedicine.anatomical_structureAttributable risk030211 gastroenterology & hepatologyFemalebusinessHumanDemography
researchProduct

The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study

2021

Item does not contain fulltext BACKGROUND: Esophagectomy is a technically challenging procedure, associated with significant morbidity. The introduction of minimally invasive esophagectomy (MIE) has reduced postoperative morbidity. OBJECTIVE: Although the short-term effect on complications is increasingly being recognized, the impact on long-term survival remains unclear. This study aims to investigate the association between postoperative complications following MIE and long-term survival. METHODS: Data were collected from the EsoBenchmark Collaborative composed by 13 high-volume, expert centers routinely performing MIE. Patients operated between June 1, 2011 and May 31, 2016 were included…

medicine.medical_specialtySurvivalmedicine.medical_treatmentPostoperative complications03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingmedicineClinical endpointMinimally invasive esophagectomybusiness.industryIncidence (epidemiology)Organ dysfunctionHazard ratioEsophageal cancermedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Esophagectomy030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgerymedicine.symptomComplicationbusinessCohort study
researchProduct

Linking scientific and practical knowledge in innovation systems

2011

New research indicates that firms combining the science-based STI (Science, Technology, Innovation) and the experience-based DUI (Doing, Using, Interacting) modes of innovation are more efficient when it comes to improving innovation capacity and competitiveness. With regard to innovation policy, the STI mode calls for a supply driven policy, typically aimed to commercialise research results. The DUI mode suggests a demand driven policy approach, such as supporting the development of new products or services to specific markets. This paper analyses how the two types of innovation policy and the two innovation modes can be combined in regional innovation systems. The analysis builds on studi…

jel:O33jel:O38innovation policy; scientific knowledge; practical knowledge; regional innovation systems; food industry; Norway; Sweden
researchProduct